Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference
BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) — Decibel Therapeutics (Nasdaq:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will present a corporate overview at the SVB Securities Global Biopharma Conference being held virtually on Thursday, February 16, 2023 at 9:20 a.m. E.T.
Related news for (DBTX)
- DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. – DBTX
- Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
- Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO